New York blog main

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

4 hours ago   |   Xconomy

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is...
Read more ...

Experimental anti-malarial drug shows promise in first clinical trial

5 hours ago   |   ScienceDaily

Malaria is a leading killer of children worldwide, and new drugs are needed. New research reports encouraging early clinical results with a new compound.
Read more ...

UC San Diego to Advance Stem Cell Therapies in New Space Station Lab

7 hours ago   |   San Diego Biotechnology


Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

Organovo Future Unclear After Shareholders Reject Tarveda Merger

8 hours ago   |   Xconomy

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a...
Read more ...

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

8 hours ago   |   Pacific Biosciences

Image by Miroslava Chrienova from Pixabay Our team is proud to announce that PacBio has been working closely with customers to help in the fight against the COVID-19 pandemic...
Read more ...

Extraction of Recombinant Periplasmic Proteins Under Industrially Relevant Process Conditions: Selectivity and Yield Strongly Depend on Protein Titer and Methodology

9 hours ago   |   Wiley   |   2 articles

Abstract In this work, we attempted to identify a method for the selective extraction of periplasmic endogenously expressed proteins, which is applicable at an industrial...
Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

13 hours ago   |   Xconomy

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis...
Read more ...

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine

14 hours ago   |   San Diego Biotechnology

SAN DIEGO, April 8, 2020 /PRNewswire/ - Medical Marijuana, Inc. , the first-ever publicly traded cannabis company in the United States that launched the world's first-ever...
Read more ...

New research suggests in-womb gene correction

16 hours ago   |   ScienceDaily   |   2 articles

New research led by hearing scientists suggests an avenue to treat and prevent intractable genetic disorders before birth. Researchers, working with mice, injected a specially...
Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

17 hours ago   |   Xconomy   |   2 articles

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the...
Read more ...


Register you to post on BioTech Mag

Free Registration

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the... Read more ...

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is... Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

Organovo Future Unclear After Shareholders Reject Tarveda Merger

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a... Read more ...

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

Image by Miroslava Chrienova from Pixabay Our team is proud to announce that PacBio has been working closely with customers to help in the fight against the COVID-19 pandemic... Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis... Read more ...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its candidate in healthy volunteers. The... Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including... Read more ...

Creating Consistent Value in Biotech Without Diluting Stakeholders

Creating Consistent Value in Biotech Without Diluting Stakeholders

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide... Read more ...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us... Read more ...

Community Health Watch Study to Enhance the COVID-19 Pandemic Response

We're facing times that many of us could never have imagined due to COVID-19. We want to improve how health care systems respond to pandemics. Through the “Pandemic Response... Read more ...